Bortezomib-Resistant Nuclear Factor κB Expression in Stem-Like Cells in Mantle Cell Lymphoma

Experimental Hematology - Netherlands
doi 10.1016/j.exphem.2011.10.004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Nuclear Factor-κB Regulates Cyclooxygenase-2 Expression and Cell Proliferation in Human Gastric Cancer Cells

Laboratory Investigation
Forensic MedicinePathologyCell BiologyMolecular Biology
2001English

Bortezomib Prevents Development of Cytarabine Resistance in a Mantle Cell Lymphoma in Vitro Model

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Targeting WNT Pathway in Mantle Cell Lymphoma-Initiating Cells

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2015English

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Polo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma

Lymphoma
2013English

Transcription Factor Six2 Induces a Stem Cell Like Phenotype in Renal Cell Carcinoma Cells

FEBS Open Bio
BiochemistryGeneticsMolecular Biology
2019English

Efficacy of Subcutaneous Bortezomib in the Management of Patients With Multiple Myeloma or Relapsed Mantle Cell Lymphoma

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2014English

Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2017English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Cancer
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy